In the past week, SAVA stock has gone down by -7.11%, with a monthly decline of -5.18% and a quarterly surge of 10.69%. The volatility ratio for the week is 3.86%, and the volatility levels for the last 30 days are 6.29% for Cassava Sciences Inc. The simple moving average for the past 20 days is -4.33% for SAVA’s stock, with a 14.01% simple moving average for the past 200 days.
Is It Worth Investing in Cassava Sciences Inc (NASDAQ: SAVA) Right Now?
The 36-month beta value for SAVA is also noteworthy at -0.62. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 2 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for SAVA is 42.38M, and at present, short sellers hold a 44.68% of that float. The average trading volume of SAVA on October 31, 2024 was 2.49M shares.
SAVA) stock’s latest price update
Cassava Sciences Inc (NASDAQ: SAVA)’s stock price has gone decline by -1.96 in comparison to its previous close of 26.52, however, the company has experienced a -7.11% decrease in its stock price over the last five trading days. marketbeat.com reported 2024-10-30 that Cassava Sciences Inc. NASDAQ: SAVA is a biotech developing treatments for Alzheimer’s disease. The company has a lot of controversy over its lead drug, simufilam, which attempts to go further than alleviate symptoms but actually modify the underlying biology of the disease.
Analysts’ Opinion of SAVA
Many brokerage firms have already submitted their reports for SAVA stocks, with H.C. Wainwright repeating the rating for SAVA by listing it as a “Buy.” The predicted price for SAVA in the upcoming period, according to H.C. Wainwright is $116 based on the research report published on October 08, 2024 of the current year 2024.
B. Riley Securities gave a rating of “Neutral” to SAVA, setting the target price at $44 in the report published on November 16th of the previous year.
SAVA Trading at -7.86% from the 50-Day Moving Average
After a stumble in the market that brought SAVA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -38.39% of loss for the given period.
Volatility was left at 6.29%, however, over the last 30 days, the volatility rate increased by 3.86%, as shares sank -3.49% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -12.93% lower at present.
During the last 5 trading sessions, SAVA fell by -7.11%, which changed the moving average for the period of 200-days by +1.01% in comparison to the 20-day moving average, which settled at $27.18. In addition, Cassava Sciences Inc saw 15.50% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for SAVA
Current profitability levels for the company are sitting at:
- -58.69 for the present operating margin
- 0.42 for the gross margin
The net margin for Cassava Sciences Inc stands at -6.55. The total capital return value is set at -0.73. Equity return is now at value -8.35, with -6.97 for asset returns.
Currently, EBITDA for the company is -104.43 million with net debt to EBITDA at 1.51. When we switch over and look at the enterprise to sales, we see a ratio of 442.97. The receivables turnover for the company is 1.63for trailing twelve months and the total asset turnover is 0.01. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.07.
Conclusion
In summary, Cassava Sciences Inc (SAVA) has had a mixed performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
